ProMIS Neurosciences, Inc.

$10.60-0.47%($-0.05)
TickerSpark Score
46/100
Weak
80
Valuation
20
Profitability
15
Growth
84
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMN research report →

52-Week Range13% of range
Low $6.27
Current $10.60
High $39.75

Companywww.promisneurosciences.com

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

CEO
Neil K. Warma
IPO
2007
Employees
7
HQ
Toronto, ON, CA

Price Chart

-19.27% · this period
$28.00$17.38$6.76May 20Nov 18May 20

Valuation

Market Cap
$13.86M
P/E
-1.70
P/S
0.00
P/B
1.14
EV/EBITDA
1.22
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-237.99%
ROIC
-68.02%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-39,719,147 · -1529.33%
EPS
$-22.61 · -922.18%
Op Income
$-40,167,308
FCF YoY
-103345.22%

Performance & Tape

52W High
$39.75
52W Low
$6.27
50D MA
$13.20
200D MA
$12.19
Beta
-0.18
Avg Volume
44.43K

Get TickerSpark's AI analysis on PMN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 22, 26Kirwin Patrick D.buy4,000
Mar 5, 26Williams Eugenebuy2,000
Mar 4, 26Williams Eugenebuy2,000
Mar 3, 26Williams Eugenebuy1,000
Mar 2, 26Williams Eugenebuy1,000
Feb 3, 26ABG V-SIV IX Ltdother0
Feb 3, 26ABG V-SIV IX Ltdother700,741
Feb 19, 26Kaplan Johannebuy1,629
Feb 3, 26Cashman Neilother4,122
Feb 3, 26Cashman Neilother4,122

Our PMN Coverage

We haven't published any research on PMN yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate PMN Report →

Similar Companies